AlloLife - Life After Transplantation

Launched by UNIVERSITY HOSPITAL, ESSEN · Oct 8, 2021

Keywords

ClinConnect Summary

The AlloLife trial is designed to help improve the quality of life for people who have survived an allogeneic stem cell transplant, a treatment often used for blood cancers. After this type of transplant, many patients can live longer, but they may also face long-term health issues. This study aims to address those challenges and support survivors in their journey after treatment.

To participate in this trial, individuals must be over 18 years old, have undergone an allogeneic stem cell transplant at least 20 days prior, and be in a good health status (level 0-3 on the ECOG scale). Participants will need access to an internet-connected device and will use a wearable device and a chatbot app for health updates and psychological support throughout the study. The trial is not yet recruiting, but it will provide survivors with resources and support to enhance their well-being after transplantation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18
• • Patients with performed allogeneic stem cell transplantation any type of donor, stem cell source, GVHD prophylaxis or conditioning regimen and at least at day +20 after HCT.
• • Hematologic Remission after HCT at study entrance, MRD positive patients are allowed to enter the study
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
• • Signature of informed and written consent by the subject or by the subject's legally acceptable representative for patients under guardianship or trusteeship to participate in the study
• • Access to an internet connected device (smartphone/tablet/computer)
• • Able to understand and communicate in the respective language
• • Consent to use a wearable device through the time of the study
• • Consent to use a chatbot application for both healthcare data exchange and psychologic intervention
• Exclusion Criteria:
• • Missing consent to use a wearable device and contribute personal data collected at the point of life to the study
• • ECOG performance status of 4
• • Relapse of the disease at study inclusion
• • Uncontrolled systemic infection
• • Diagnosis of a secondary malignancy requiring systemic therapy
• • Reported ongoing severe depression or potential suicidal ideation
• • Vulnerable patients such as: minor, persons deprived of liberty, persons in Intensive Care Unit unable to provided informed consent prior to the intervention
• • Other ongoing interventional protocol that might interfere with the current study primary endpoint